Anaemia and its risk factors and association with treatments in patients with diabetes: A cross-sectional study.


Journal

Diabetes & metabolism
ISSN: 1878-1780
Titre abrégé: Diabetes Metab
Pays: France
ID NLM: 9607599

Informations de publication

Date de publication:
02 2021
Historique:
received: 10 04 2020
revised: 08 05 2020
accepted: 14 05 2020
pubmed: 29 5 2020
medline: 27 1 2022
entrez: 29 5 2020
Statut: ppublish

Résumé

Anaemia is frequently seen in patients with diabetes and the main cause is renal failure. At all stages of renal failure, however, the prevalence of anaemia is higher in diabetes patients than expected for their glomerular filtration rate, suggesting that causes of anaemia other than renal failure are at work. The present cross-sectional study was conducted to investigate the possible iatrogenic causes of anaemia in patients with diabetes. This was a hospital-based cross-sectional study of all patients who had biological and clinical data covering a 2-year period. All had been in contact with the diabetes department either as outpatients or as inpatients mostly for educational purposes. Clinical factors, including type of diabetes, known diabetes complications, treatments received and biological data, were reviewed for their possible involvement in anaemia. A total of 4145 consecutive patients were included. Anaemia was observed in 1065 (25.7%) of them. Patients with anaemia were more frequently women and those with longer durations of diabetes. Haemoglobin concentrations were decreased, and prevalence of anaemia was increased at all stages of renal failure, already at stage 2, KDIGO classification. Anaemia patients were more frequently taking insulin, antiplatelet agents and renin-angiotensin system blockers (RASBs). After exclusion of patients with specific causes of anaemia, logistic regression analysis of all parameters correlated with anaemia on univariate analysis revealed that anaemia was associated with gender, antiplatelet agents and RASBs. This study has confirmed that anaemia is frequently seen in diabetes patients and strongly associated with renal failure (already at stage 2). Our observations highlight the adjuvant role of drugs, particularly RASBs, in the risk of anaemia in patients with diabetes.

Sections du résumé

BACKGROUND
Anaemia is frequently seen in patients with diabetes and the main cause is renal failure. At all stages of renal failure, however, the prevalence of anaemia is higher in diabetes patients than expected for their glomerular filtration rate, suggesting that causes of anaemia other than renal failure are at work. The present cross-sectional study was conducted to investigate the possible iatrogenic causes of anaemia in patients with diabetes.
SUBJECTS AND METHODS
This was a hospital-based cross-sectional study of all patients who had biological and clinical data covering a 2-year period. All had been in contact with the diabetes department either as outpatients or as inpatients mostly for educational purposes. Clinical factors, including type of diabetes, known diabetes complications, treatments received and biological data, were reviewed for their possible involvement in anaemia.
RESULTS
A total of 4145 consecutive patients were included. Anaemia was observed in 1065 (25.7%) of them. Patients with anaemia were more frequently women and those with longer durations of diabetes. Haemoglobin concentrations were decreased, and prevalence of anaemia was increased at all stages of renal failure, already at stage 2, KDIGO classification. Anaemia patients were more frequently taking insulin, antiplatelet agents and renin-angiotensin system blockers (RASBs). After exclusion of patients with specific causes of anaemia, logistic regression analysis of all parameters correlated with anaemia on univariate analysis revealed that anaemia was associated with gender, antiplatelet agents and RASBs.
CONCLUSION
This study has confirmed that anaemia is frequently seen in diabetes patients and strongly associated with renal failure (already at stage 2). Our observations highlight the adjuvant role of drugs, particularly RASBs, in the risk of anaemia in patients with diabetes.

Identifiants

pubmed: 32461154
pii: S1262-3636(20)30083-5
doi: 10.1016/j.diabet.2020.05.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101164

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

M Brière (M)

Service de diabétologie, Hôpital Cochin, AP-HP, Centre-Université de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.

M Diedisheim (M)

Service de diabétologie, Hôpital Cochin, AP-HP, Centre-Université de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.

L Dehghani (L)

Service de diabétologie, Hôpital Cochin, AP-HP, Centre-Université de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.

D Dubois-Laforgue (D)

Service de diabétologie, Hôpital Cochin, AP-HP, Centre-Université de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.

E Larger (E)

Service de diabétologie, Hôpital Cochin, AP-HP, Centre-Université de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France. Electronic address: etienne.larger@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH